What type of anti-cancer targeted drug does Brigatinib/Brigatinib (Embry) belong to?

Brigatinib/Brigatinib (Brigatinib) is a small molecule targeted drug that is a tyrosine kinase inhibitor (TKI). It specifically acts on the ALK (anaplastic lymphoma kinase) gene mutation of cancer cells, inhibiting the abnormal activity of the gene, thereby preventing the growth and expansion of tumor cells. ALK gene mutations are commonly found in non-small cell lung cancer (NSCLC), especially in younger patients or non-smokers. Brigatinib exerts an effective anti-cancer effect by targeting this gene mutation.

The ALK gene is a gene encoding a tyrosine kinase, and mutations in it can lead to uncontrolled proliferation of cancer cells. Brigatinib, as an ALk-targeting drug, can inhibit the growth of these cancer cells. By binding to the ALK protein and inhibiting its kinase activity, it blocks intracellular signaling, a process that should promote cell growth and division. The mechanism of action of brigatinib is similar to other TKI drugs, but it has stronger anti-cancer effects and can effectively overcome some common drug resistance.

The treatment direction of brigatinib is mainly for patients with advanced non-small cell lung cancer who showALK gene mutations. Because these patients are often insensitive to conventional chemotherapy, brigatinib provides a more effective treatment option through its precise targeting mechanism. In addition, brigatinib is also being studied in clinical trials for other types of cancer, particularly those involving abnormalities in the ALk signaling pathway.

As a targeted drug, brigatinib can usually reduce damage to normal cells during treatment, thereby alleviating the side effects caused by traditional chemotherapy drugs. Its targeted effect not only improves the treatment effect, but also improves the patient's quality of life. Compared with other chemotherapy drugs, brigatinib has mild side effects, and it often shows significant efficacy in patients with ALK mutation-positive non-small cell lung cancer.

Reference materials:https://www.alunbrig.com/